跳至主要内容
临床试验/CTRI/2020/01/022862
CTRI/2020/01/022862已完成不适用

Genetic analysis and development of liquid biopsy tests for early detection and treatment monitoring of cervical cancer

DBT Ramalingaswamy Fellowship1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2020年1月20日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
1. The primary outcome is to measure the percentage of cervical cancers that can be detected using a liquid biopsy. Samples from follow up timepoints will be useful for analysis of treatment and their prognostic value for success of brachytherapy.

研究概览

简要总结

The current study aims to test if a digital PCR based assay for detection of HPV in circulating tumor DNA (ctDNA) is a sensitive and a sustainable tool for early detection of CIN2 and CIN3 cervical cancer. Treatment monitoring and detection of minimal residual disease in more invasive HPV associated cancers.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
Female

入选标准

  • Inclusion criteria includes Patients 18 years old or older with suspicion of cervical cancer referred to Manipal Comprehensive Cancer Center.

排除标准

  • Patients diagnosed with inflammatory or haematological disease after the age of 18 will be excluded from the study.

结局指标

主要结局

1. The primary outcome is to measure the percentage of cervical cancers that can be detected using a liquid biopsy. Samples from follow up timepoints will be useful for analysis of treatment and their prognostic value for success of brachytherapy.

时间窗: 0, 3, 6 months. Follow up at 36 months.

2.Measure recurrence in cervical cancer patients through serial monitoring with liquid biopsies (blood sample).

时间窗: 0, 3, 6 months. Follow up at 36 months.

3.Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.

时间窗: 0, 3, 6 months. Follow up at 36 months.

次要结局

  • Identification of novel cervical cancer susceptible genes or genetic markers in the Indian population.(Pretreatment sample)

研究者

发起方
DBT Ramalingaswamy Fellowship
申办方类型
Government funding agency

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical CancerCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedInfiltrating Cervical CarcinomaMetastatic Cervical CarcinomaRecurrent Cervical CarcinomaStage I Cervical Cancer FIGO 2018Stage IA Cervical Cancer FIGO 2018Stage IA1 Cervical Cancer FIGO 2018Stage IA2 Cervical Cancer FIGO 2018Stage IB Cervical Cancer FIGO 2018Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer FIGO 2018Stage IB3 Cervical Cancer FIGO 2018Stage II Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Stage IIA1 Cervical Cancer FIGO 2018Stage IIA2 Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018Stage III Cervical Cancer FIGO 2018Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Stage IIIC Cervical Cancer FIGO 2018Stage IIIC1 Cervical Cancer FIGO 2018Stage IIIC2 Cervical Cancer FIGO 2018Stage IV Cervical Cancer FIGO 2018Stage IVA Cervical Cancer FIGO 2018Stage IVB Cervical Cancer FIGO 2018
NCT04574635Mayo Clinic18
已完成
不适用
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial NeoplasiaCervix LesionCervical Cancer
NCT04274465UNC Lineberger Comprehensive Cancer Center145
招募中
不适用
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following TreatmentCervical Cancer
NCT04743674UNC Lineberger Comprehensive Cancer Center30
进行中(未招募)
不适用
Post-treatment Surveillance in HPV+ Oropharyngeal SCCHPVOropharyngeal Squamous Cell Carcinoma
NCT04965792Dana-Farber Cancer Institute150
已完成
不适用
A Study to Identify Markers in Blood and Tissue of HPV ClearanceHPV Infections
NCT00711815University of Alabama at Birmingham197